Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Moodys
McKesson
Merck

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020313

See Plans and Pricing

« Back to Dashboard

NDA 020313 describes MIACALCIN, which is a drug marketed by Mylan Ireland Ltd and is included in two NDAs. It is available from one supplier. Additional details are available on the MIACALCIN profile page.

The generic ingredient in MIACALCIN is calcitonin salmon. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the calcitonin salmon profile page.
Summary for 020313
Tradename:MIACALCIN
Applicant:Mylan Ireland Ltd
Ingredient:calcitonin salmon
Patents:0
Formulation / Manufacturing:see details
Paragraph IV (Patent) Challenges for 020313
Tradename Dosage Ingredient NDA Submissiondate
MIACALCIN SPRAY, METERED;NASAL calcitonin salmon 020313

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SPRAY, METERED;NASALStrength200 IU/SPRAY
Approval Date:Aug 17, 1995TE:RLD:Yes

Expired US Patents for NDA 020313

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Ireland Ltd MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995   Start Trial   Start Trial
Mylan Ireland Ltd MIACALCIN calcitonin salmon SPRAY, METERED;NASAL 020313-002 Aug 17, 1995   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Express Scripts
AstraZeneca
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.